Добавил:
Sekretar
kiopkiopkiop18@yandex.ru
t.me/Prokururor I Вовсе не секретарь, но почту проверяю
Опубликованный материал нарушает ваши авторские права? Сообщите нам.
Вуз:
Предмет:
Файл:Ординатура / Хирургия / Библиотека им академика М.И. Перельмана / Книга_3591_Библиотеки_им_академика_М_И_Перельмана.pdf
X
- •Preface
- •Acknowledgments
- •Contents
- •About the Editor
- •1.6 Acute Gastrointestinal Bleeding
- •1.7 Transjugular Intrahepatic Portosystemic Shunt
- •1.8 Conclusion
- •References
- •2.1 Introduction
- •2.2 History-Taking
- •2.4 Pre-procedure Imaging
- •2.5 Pre-procedure Investigations
- •2.8 Informed Consent
- •2.10 Part Preparation
- •2.11 Antibiotic Prophylaxis
- •References
- •3.1 Introduction
- •3.2 Ultrasonography
- •3.2.1 Advantages
- •1.1 Introduction
- •1.2 Early Beginnings
- •1.3 Catheter-Directed Thrombolysis
- •1.4 Stents
- •1.5 Coronary Angiography
- •3.2.3 Limitations
- •3.3 Fluoroscopy
- •3.3.1 Indications
- •3.3.2 Interventional Fluoroscopy
- •3.3.2.1 Digital Subtraction Angiography
- •3.4 Computed Tomography
- •3.4.2 Indications
- •3.4.3 Limitations
- •3.5 Magnetic Resonance Imaging
- •3.5.3 Limitations
- •3.6.3 Remove Anti-scatter Grid
- •3.6.4 Pulsed Fluoroscopy
- •3.6.5 Checklist
- •3.9 Conclusion
- •References
- •4.1 Introduction
- •4.2 Pharmaceutical Agents
- •4.2.1 Contrast Agents
- •4.2.2 Iodinated Contrast Media (ICM)
- •Pathogenesis
- •Risk Factors
- •Diagnosis
- •Risk Threshold
- •4.5 Conclusion
- •References
- •4.3 Carbon Dioxide
- •4.3.1 Indication
- •4.3.2 Contraindications
- •4.3.3 Equipment
- •4.3.4 Preparation
- •4.3.5 Technique
- •4.3.6 Complications
- •4.3.7 Advantages
- •4.3.8 Disadvantages
- •4.4.1 Thrombolytics
- •First-Generation Thrombolytic Agents
- •Second-Generation Thrombolytic Agents
- •Third-Generation Thrombolytic Agents
- •4.4.1.2 Contraindications
- •4.4.2 Anticoagulants
- •4.4.2.1 Unfractionated Heparin (UFH)
- •Mechanism
- •Indications
- •4.4.2.2 Low-Molecular-Weight Heparin (LMWH)
- •Mechanism
- •Indications
- •Special Considerations
- •4.4.2.3 Warfarin
- •Mechanism
- •Indications
- •Special Considerations
- •4.4.3 Antiplatelet Drugs
- •4.4.3.1 Aspirin
- •Mechanism
- •Recommendations
- •4.4.3.2 Clopidogrel
- •Mechanism
- •Recommendations
- •4.4.3.3 Glycoprotein IIb/IIIa Inhibitors (GPI)
- •Mechanism
- •Recommendations
- •4.4.4 Vasodilators
- •4.4.4.1 Nitroglycerine
- •Mechanism
- •Indications
- •4.4.4.2 Verapamil
- •Mechanism
- •Indications
- •Contraindications
- •Complications
- •4.4.5 Vasoconstrictors
- •4.4.5.1 Mechanism
- •4.4.5.3 Indication
- •4.4.6 Prothrombotics
- •4.4.6.1 Mechanism
- •4.4.6.3 Indications
- •4.4.6.5 Special Considerations
- •5.1 Introduction
- •5.2 Pre-procedure Tasks
- •5.2.4 Pre-anesthetic Evaluation
- •5.3 Anesthesia Techniques
- •5.3.1 Local Anesthesia
- •5.4 Pediatric IR Procedures
- •5.5 Anesthesia Considerations
- •5.11 Conclusion
- •References
- •6.1 Introduction
- •6.3 Pre-procedural Workup
- •6.3.1 Prothrombin Time (PT-INR)
- •6.3.3 Viscoelastic Tests
- •6.4.1 Procedure-Related Bleeding Risk
- •6.5.1 Chronic Liver Disease
- •6.5.2 Chronic Kidney Disease
- •6.5.3 Thrombocytopenia
- •6.5.4 Disseminated Intravascular Coagulation (DIC)
- •6.5.5 Malignancy
- •6.6 Bridge Therapy
- •6.7 Deep Vein Thrombosis (DVT)
- •6.8 Atrial Fibrillation (AF)
- •6.9 Coronary Stents
- •6.10 Conclusion
- •References
- •7.1 Introduction
- •7.4 Embolic Agent Selection
- •7.5.1 Gelfoam Embolization
- •7.5.2 Coil Embolization
- •7.5.3 Amplatzer Vascular Plug Embolization
- •7.5.4 Glue Embolization
- •7.6 Clinical Applications
- •7.6.1.1 Endovascular Approach
- •Parent Artery Preservation [16, 17]
- •Stent or Balloon-Assisted Coiling [20, 21]
- •Multi-Layered Flow-Diverting Stents [22]
- •7.6.1.2 Parent Artery Occlusion
- •Sandwich Technique [19–22]
- •7.6.1.3 Percutaneous Approach [16, 17, 24, 25]
- •7.6.2 Tumoral Embolization
- •7.6.3 AVM Embolization
- •7.6.5 Special Scenario
- •7.6.5.1 Provocative Angiography
- •7.6.5.2 Lower GI Bleeding
- •7.6.5.3 Hepatic Artery Aneurysm
- •7.6.5.4 Renal Artery Aneurysm (RAA)
- •7.7 Newer Embolizations
- •7.7.1 Genicular Artery Embolization
- •7.8 Conclusion
- •References
- •8.1 Introduction
- •8.2 Puncture Needles
- •8.3 Guidewires
- •8.4 Sheath System
- •8.5 Catheters
- •8.6 Microcatheters
- •8.7 Embolizing Agents
- •8.7.1 Gelatin Foam
- •8.7.2 Autologous Blood Clot
- •8.7.3 Thrombin
- •8.7.4 Coils
- •8.7.5 Vascular Plugs
- •8.7.6 Particulate Agents
- •8.7.7 Liquid Embolic Agents
- •8.8 Detachable Balloons
- •References
- •9.1 Introduction
- •9.2 Balloons
- •9.2.1 Basics
- •9.2.7 Balloon Ratings
- •9.2.11 Balloon Catheter Design
- •9.2.13 Complications
- •9.2.14 Occlusion Balloons
- •9.2.15 Angioplasty–Pearls
- •9.3 Stents
- •9.3.4 Raw Material Form
- •9.3.5 Fabrication
- •9.3.6 Geometry
- •9.3.7 Additions
- •9.3.8 Drug-Eluting Stents
- •9.3.10.1 Arterial Indications
- •9.3.10.2 Venous Indications
- •9.3.10.3 Non-vascular Indications
- •9.3.11 Uncovered vs. Covered (PTFE) SEMS
- •9.3.12 Stent Grafts
- •References
- •10: Vascular Access
- •10.1 Introduction
- •10.2 Indications
- •10.3 Hardware
- •10.3.1 Intravenous Cannula
- •10.3.2 Puncture Needle
- •10.3.3 Arterial Access Sheath
- •10.4 Local Anesthesia
- •10.6 General Considerations Before Procedure
- •10.7 Arterial Access
- •10.7.2 Arterial Access Sites
- •10.7.2.1 Common Femoral Artery
- •10.7.2.2 High Brachial or Axillary Artery
- •10.7.2.3 Radial Artery
- •10.7.2.4 Pedal Access [3]
- •10.7.2.5 Others
- •10.8 Post-procedure Care
- •10.8.1 Manual Compression
- •10.8.2 Vascular Closure Devices (VCD)
- •10.9 Complications [5–8]
- •10.10 Venous Access
- •10.10.1 Common Femoral Vein
- •10.10.2 Internal Jugular Vein
- •10.10.3 Subclavian Vein Access
- •10.10.4 Upper Extremity Vein Access
- •10.11 Conclusion
- •References
- •11: Neurointerventions Including Aneurysm Interventions
- •11.1 Introduction
- •11.2 Neurovascular Interventions
- •11.3.1 Introduction
- •11.3.3 Clinical Presentation
- •11.3.8 Endovascular Techniques
- •11.3.9 General Technical Guidelines
- •11.3.10 Simple Coiling
- •11.3.11 Balloon-Assisted Coiling
- •11.3.12 Stent-Assisted Coiling
- •11.3.13 Flow Diverter/Braided Stents
- •11.3.14 Stent Graft
- •11.3.15 Parent Artery Occlusion
- •11.3.16 Endosaccular Devices
- •11.4.1 Pathophysiology
- •References
- •12.1 Introduction
- •12.4 Thrombectomy Techniques
- •12.5 Aspiration Technique
- •12.5.1 Stentriever Technique
- •12.6 Combination Technique
- •12.7 Balloon Guide Catheters (BGC)
- •12.8 Special Situations
- •12.8.1 Posterior Circulation Stroke
- •12.8.2 Tandem Occlusions
- •12.8.3 Intracranial Atherosclerotic Disease (ICAD)
- •12.8.4 Medium Vessel Occlusions (MeVO)
- •12.9 Complications
- •12.10 Immediate Post-procedure Care
- •References
- •13.1 Introduction
- •13.2 Brain AVMs
- •13.2.1 Introduction
- •13.2.2 Epidemiology
- •Embolic Agents
- •Embolization Techniques
- •Embolization by Copolymers: Technical Aspects
- •13.3 Intracranial Dural Arterio-Venous Fistulas (DAVFs)
- •13.4 VGAM
- •13.5 Spinal Vascular Malformations
- •13.5.1 Introduction
- •13.5.2 Anatomy
- •13.5.4.3 Spinal Epidural AVMs
- •13.5.4.4 Metameric AVMs
- •References
- •14: Other Neurointerventions
- •14.1 Introduction
- •14.2 Direct CCF
- •14.2.2 Treatment
- •14.3 Epistaxis
- •14.4 Neck Vessel Pathologies
- •14.4.2 Etiopathogenesis
- •14.4.3 Clinical Presentation
- •14.4.4 Management
- •References
- •15.1 Introduction
- •15.4.2 Embolization Agents
- •15.5 Conclusion
- •References
- •16: Carotid Artery Interventions
- •16.1 Introduction
- •16.2.1 Imaging
- •16.2.2.1 Symptomatic Carotid Artery Stenosis
- •16.2.2.2 Asymptomatic Carotid Artery Stenosis
- •16.2.3 Best Medical Therapy
- •16.3 Carotid Artery Stenting
- •16.3.1 Preprocedure
- •16.3.2 Hardware
- •16.3.2.1 Procedure
- •16.5 Complications
- •16.5.1 Early Complications
- •16.5.2 Late Complications
- •16.6 Internal Carotid Artery Stenting
- •16.7 Conclusion
- •References
- •18.1 Introduction
- •18.2 Anatomical Considerations
- •18.3 Aortic Dissection
- •18.3.1 Introduction
- •18.3.2.3 Natural History
- •18.3.2.4 Imaging Options
- •18.3.2.6 Conventional Management Plan
- •18.4 Aortic Aneurysms
- •18.4.1 Overview
- •18.4.4 Thoraco-Abdominal Aortic Aneurysm
- •18.4.5 Abdominal Aortic Aneurysm (AAA)
- •18.4.5.3 Endovascular Intervention
- •18.4.6.1 Epidemiology
- •18.4.6.3 Pathophysiology
- •18.4.7 PAU
- •18.4.7.1 Imaging
- •18.4.7.2 Prognosis
- •18.4.7.3 Management
- •18.4.8 PAU
- •18.5.1 Access Site
- •18.5.2 Procedure
- •18.5.3 Post-Procedure Care
- •18.5.4 Follow-Up Imaging
- •18.6.1 Device-Related Complications
- •18.6.2 Systemic Complications
- •18.7 Endoleaks
- •References
- •19: Vascular Thoracic Interventions
- •19.1 Introduction
- •19.2 Bronchial Artery Embolization (BAE)
- •19.2.1.3 Pre-Procedure Evaluation
- •19.2.2 Bronchoscopy
- •19.2.2.1 Technique
- •19.2.2.2 Post-Procedure Care
- •19.2.2.3 Complications
- •19.3 Pulmonary Artery Pseudoaneurysm (PAPA)/Pulmonary AVM (PAVM) Embolization
- •19.3.1 Pre-Procedure Evaluation
- •19.3.1.2 Technique
- •19.3.2 Post-Procedure Care
- •19.3.3 Complications
- •19.4.1 Pre-Procedure Evaluation
- •19.4.2 Technique
- •19.4.3 Complications
- •19.4.4 Post-Procedure Follow-Up
- •19.5 Thoracic Duct Interventions
- •19.5.1 Pre-Procedure Evaluation
- •19.5.2 Lymphangiography Technique
- •19.5.3 Thoracic Duct Embolization Technique
- •19.5.4 Complications
- •19.5.4.2 Central Lymphatic Access Complications
- •References
- •20.1 Introduction
- •20.2 Pulmonary Embolism
- •20.2.3 Pulmonary Angiography
- •20.2.3.1 Technique
- •20.2.3.2 Post-Procedure Care
- •20.2.3.3 Complications
- •20.2.4.1 Intravenous Thrombolysis
- •20.2.4.2 Catheter-Directed Thrombolysis
- •20.2.4.3 Mechanical Thrombectomy
- •Rheolytic Thrombectomy Devices
- •Aspiration Thrombectomy Devices
- •20.3.1 Clinical Manifestations [16, 17]
- •20.3.3 Radiological Findings
- •20.3.4 Endovascular Management
- •20.3.4.1 Pre-Procedure Evaluation
- •20.3.4.2 Technique
- •20.3.4.3 Post-Procedure Care
- •20.3.4.5 Current Evidence
- •20.4 Pulmonary Artery Aneurysm
- •20.4.1 Endovascular Management
- •20.4.1.1 Technique
- •References
- •21: Hepatic Arterial Interventions
- •21.1 Introduction
- •21.2 Hepatic Arterial Anatomy
- •21.2.1 Normal Celiac Anatomy
- •21.2.2 Normal Hepatic Artery Anatomy
- •21.2.3 Variant Anatomies
- •21.3.1.2 Contraindications
- •21.3.1.3 Patient Selection
- •21.3.1.4 Patient Preparation
- •21.3.1.6 Response Evaluation
- •21.3.1.7 TACE Failure
- •21.3.1.8 TACE Discontinuation
- •21.3.1.9 Complications
- •21.3.2 Transarterial Radioembolization (TARE)
- •21.3.2.2 Contraindications [24]
- •21.3.2.3 Agents Used
- •21.3.2.4 First Visit (Planning)
- •21.3.2.5 Second Visit (Microsphere Injection)
- •21.3.2.6 Complications
- •21.3.3 Transarterial Bland Embolization (TAE)
- •21.3.4 Hepatic Artery Infusion Chemotherapy (HAIC)
- •21.4.1 Neuroendocrine Liver Metastasis (NELM)
- •21.4.2 Other Liver Metastases
- •21.4.3 Intrahepatic Cholangiocarcinoma (IHCC)
- •21.4.4 Benign Liver Tumors
- •21.4.4.1 Hemangiomas
- •21.4.4.2 Focal Nodular Hyperplasia
- •21.4.4.3 Hepatocellular Adenoma
- •21.4.4.4 Polycystic Liver Disease
- •21.8 Hepatic Parenchyma Repopulation
- •References
- •22.1 Introduction
- •22.2 Transjugular Liver Biopsy (TJLB)
- •22.2.1 Patient Preparation
- •22.2.2 Procedure
- •22.2.3 Post-Procedural Care
- •22.2.4 Complications
- •22.3 Transjugular Intrahepatic Portosystemic Shunt (TIPS)
- •22.3.3 Pre-Procedural Evaluation [12–14]
- •22.3.4 Technique
- •22.3.5 Post-Procedural Care
- •22.3.6.1 Extrahepatic Portal Vein Puncture [18, 19]
- •22.3.6.2 Hepatic Artery Injury [18–20]
- •22.3.7 Discussion
- •22.4 Balloon-Occluded Retrograde Transvenous Obliteration (BRTO)
- •22.4.1 Indications and Contraindications of BRTO
- •22.4.2 Pre-Procedural Evaluation
- •22.4.3 Requirements
- •22.4.4 Sclerosants
- •22.4.5 Relevant Anatomy
- •22.4.6 Techniques
- •22.4.8 Discussion
- •22.5 Portal Vein Thrombosis (PVT)
- •22.6.2 HV/IVC Stenting
- •22.6.3 Tips/Dips
- •22.6.4 HV/IVC Thrombolysis
- •22.6.5 Discussion
- •22.7 Portal Vein Embolization
- •22.7.5 Pre-Procedural Evaluation
- •22.7.6 Techniques
- •22.7.7 Embolizing Materials
- •22.7.8 Hypertrophy Response
- •22.7.11 Discussion
- •22.8 Transjugular Kidney Biopsy (TJKB)
- •22.8.1 Indications
- •22.8.2 Rationale
- •22.8.3 Pre-Procedural Workup
- •22.8.4 Techniques
- •22.9 IVC Filter
- •22.9.2 Patient Preparation
- •22.9.4 Procedure
- •22.9.5 Complications [98, 102]
- •References
- •23.1 Introduction
- •23.2 Anatomy
- •23.2.1 Arterial Anatomy
- •23.2.2 Venous Anatomy
- •23.3 Arterial Interventions
- •23.3.1 Renovascular Hypertension
- •23.3.2 Atherosclerotic Renal Artery Stenosis
- •23.3.3 Non-atherosclerotic RAS
- •23.3.4 Takayasu Arteritis (TA)
- •23.3.5 Fibromuscular Dysplasia (FMD)
- •23.5.2.1 Preprocedural Evaluation
- •23.5.2.2 Preprocedural Instructions
- •23.5.2.3 Procedure
- •23.5.2.4 Angiography
- •23.5.2.5 Balloon Angioplasty
- •23.5.2.6 Cutting Balloon Angioplasty
- •23.5.2.7 Stenting
- •23.5.2.9 Post-Procedural Care
- •23.5.2.10 Complications
- •23.6.1 Procedure
- •23.7 Renal Artery Aneurysms (RAAs)
- •23.8.1 Etiology
- •23.8.2 Clinical Presentation
- •23.8.3 Endovascular Management
- •23.9.1 Angiomyolipoma
- •23.9.2 Renal Cell Carcinoma (RCC)
- •23.10 Venous Interventions
- •23.10.1 Nutcracker Syndrome (NCS)
- •23.10.1.1 Diagnosis
- •23.10.1.2 Management
- •23.10.1.3 Endovascular Management
- •23.10.1.4 Procedure
- •23.10.1.5 Complications
- •23.10.2 Renal Vein Thrombosis
- •23.10.2.1 Clinical Presentation
- •23.10.2.2 Management
- •23.10.2.4 Procedure
- •References
- •24.1 Introduction
- •24.2 Relevant Anatomy
- •24.3 Mesenteric Ischemia
- •24.3.1 Clinical Features
- •24.3.2 Imaging
- •24.3.3 Treatment
- •24.3.3.2 Intra-Arterial Thrombolysis
- •24.3.3.3 Mechanical Thrombectomy
- •24.4 Gastrointestinal Hemorrhage
- •24.4.1 Clinical Features
- •24.4.2 Endoscopy
- •24.4.3 Imaging
- •24.4.4.2 Complications
- •24.5 Bariatric Embolization
- •24.5.1 Technique
- •References
- •25.1 Introduction
- •25.2 Uterine Artery Embolization (UAE)
- •25.2.1 Indications [1, 2]
- •25.2.2 Contraindications [1, 2]
- •25.2.3 Relevant Vascular Anatomy [2]
- •25.2.4 Preprocedural Evaluation
- •25.2.5 Technique
- •25.2.6 Post-Procedural Care
- •25.2.7 Complications
- •25.2.8 Outcome
- •25.3 Prostatic Artery Embolization (PAE)
- •25.3.1 Rationale Behind PAE
- •25.3.2 Indications [17, 18]
- •25.3.3 Contraindications [18]
- •25.3.4 Preprocedural Evaluation [17]
- •25.3.5 Clinical Assessment
- •25.3.7 Imaging
- •25.3.7.1 Ultrasonography (USG)
- •25.3.7.2 Computed Tomography (CT)
- •25.3.7.3 Magnetic Resonance Imaging (MRI)
- •25.3.9 Relevant Vascular Anatomy
- •25.3.10 Technique
- •25.3.11 Complications
- •25.3.12 Post-Procedural Follow-Up
- •25.3.13 Outcome
- •25.4 Varicocele Embolization
- •25.4.1 Indications [22, 26]
- •25.4.4 Relevant Vascular Anatomy
- •25.4.5 Preprocedural Evaluation [23, 25]
- •25.4.6 Technique
- •25.4.6.2 Venous Access [25, 27, 28]
- •25.4.6.3 Venography [25, 27]
- •25.4.6.4 Embolization [25, 27, 29–31]
- •25.4.7 Post-Procedural Care
- •25.4.8 Complications
- •25.4.9 Outcome
- •25.5 Pelvic Congestion Syndrome
- •25.5.1 Indication [38]
- •25.5.2 Contraindications [38]
- •25.5.3 Preprocedural Evaluation
- •25.5.4 Relevant Vascular Anatomy
- •25.5.5 Technique
- •25.5.6 Post-Procedural Care
- •25.5.7 Complications
- •25.5.8 Outcome
- •25.6 Penile Angiography
- •25.6.1 Penile Vascular Anatomy
- •25.6.2 Technique
- •25.6.3 Complications
- •25.6.4 Outcome
- •References
- •26.2 Peripheral Arterial Disease (PAD)
- •26.2.1 Introduction
- •26.2.5.1 Non-imaging/Functional Modalities
- •26.2.5.2 Imaging Evaluation
- •26.2.6 Management Strategies
- •26.2.6.3 Revascularization Strategies
- •26.3.2 Preprocedural Evaluation
- •26.3.5 Complications
- •26.3.6 Stenting
- •26.3.7 Post-Procedure
- •26.5 Recent Advances
- •26.5.2 Drug-Eluting Technology
- •26.5.3 Bioresorbable Stents
- •26.5.6 Pedal Arch Revascularization
- •26.5.7 Percutaneous Deep Vein Arterialization (DVA)
- •26.6 Acute Limb Ischemia
- •26.7 Popliteal Artery Entrapment Syndrome (PAES)
- •26.8 Genicular Artery Embolization (GAE)
- •References
- •27.1 Introduction
- •27.2 Relevant Anatomy
- •27.3 Varicose Veins
- •27.3.1 Clinical Evaluation
- •27.3.2 Physical Examination
- •27.3.3 Sonological Evaluation
- •27.3.3.1 Duplex Sonographical Evaluation
- •27.3.5.1 Thermal Ablation
- •Endovenous Laser Ablation
- •Radiofrequency Ablation
- •Endovenous Steam Ablation
- •27.3.5.2 Non-thermal Ablative Methods
- •Foam Sclerotherapy
- •Cyanoacrylate Closure (CAC)
- •Mechanochemical Ablation (MOCA)
- •Cryosclerosis
- •27.4 Deep Vein Thrombosis
- •27.4.1 Diagnosis
- •27.4.1.1 Pre-Test Probability
- •27.4.1.2 D-Dimer Assessment
- •27.4.1.3 Radiological Evaluation
- •27.4.5.1 Catheter-Directed Thrombolysis
- •Single-Session (Second-Generation) Pharmacomechanical Catheter-Directed Thrombolysis
- •27.5.1 Pulmonary Embolism (PE)
- •27.5.2 Clinical Features
- •27.5.3 Imaging Evaluation
- •27.5.4 Management
- •27.5.5 Endovascular Techniques
- •References
- •28.1 Introduction
- •28.3.2 Imaging Evaluation
- •28.4 Endovascular Management
- •28.4.1 Nonmature Fistulas
- •28.4.3 Acute Thrombosis
- •28.5 Central Venous Stenosis
- •28.7 Pseudoaneurysm
- •References
- •29.1 Introduction
- •29.2 Low-Flow Vascular Malformations
- •29.2.1.1 Pre-procedural Requirements
- •29.2.1.2 Procedure
- •29.2.1.3 Post-procedure Care
- •Ethanol
- •Detergent Sclerosant
- •Bleomycin
- •Doxycycline
- •OK-432 (Picibanil)
- •29.2.1.5 Complications
- •29.3 High-Flow Vascular Malformations
- •29.3.1.1 Pre-procedure Evaluation
- •29.3.1.2 Technique
- •29.3.1.3 Complications
- •29.4 Fibro-Adipose Vascular Anomaly (FAVA)
- •29.5 Conclusion
- •References
- •30.1 Introduction
- •30.2 Splenic Injuries
- •30.2.2 Technique
- •30.2.3 Patient Preparation
- •30.2.4 Procedure
- •30.2.5 Embolizing Agent
- •30.2.6 Post-procedural Care
- •30.2.7 Complication
- •30.3 Hepatic Injury
- •30.3.1 Background
- •30.3.2 Indication
- •30.3.3 Technique
- •30.3.4 Patient Preparation
- •30.3.6 Embolization Agent
- •30.3.7 Post-procedural Care
- •30.3.8 Complications
- •30.4 Peripheral Vascular Injuries (PVI)
- •30.4.1 Background
- •30.4.2 Indication
- •30.4.3 Patient Preparation
- •30.4.5 Embolization Agent
- •30.4.6 Post-procedural Care
- •30.4.7 Complications
- •30.5 Pelvic Trauma
- •30.5.1 Background
- •30.5.2 Indication
- •30.5.3 Technique
- •30.5.4 Patient Preparation
- •30.5.6 Embolization Agent
- •30.5.7 Complications
- •30.6 Maxillofacial Injury (MFI)
- •30.6.1 Background
- •30.6.2 Indication
- •30.6.3 Technique
- •30.6.4 Patient Preparation
- •30.6.6 Embolization Agent
- •30.6.7 Complications
- •30.7 Conclusion
- •References
- •31.1 Introduction
- •31.2 Inferior Petrosal Sinus Sampling
- •31.2.2 Cushing Syndrome (CS)
- •31.2.4 Pre-Procedure Instructions
- •31.2.5 Minimum Hardware Required
- •31.2.7 Result Interpretation
- •31.3 Adrenal Venous Sampling
- •31.3.1 Adrenal Gland Anatomy
- •31.3.2 Vascular Anatomy
- •31.3.3 Primary Hyperaldosteronism
- •31.3.5 Pre-Procedure Instructions
- •31.3.6 Minimum Hardware Required
- •31.3.8 Result Interpretation
- •31.4 Pancreatic Venous Sampling
- •31.4.1 Pancreatic Venous Anatomy
- •31.4.3 Pancreatic Neuroendocrine Tumors
- •31.4.4 Pre-Procedure Instructions
- •31.4.5 Minimum Hardware Required
- •31.4.7 Result Interpretation
- •31.5 Ovarian Venous Sampling
- •31.5.1 Anatomy
- •31.5.2 Hyperandrogenism
- •31.5.3 Pre-Procedure Instructions
- •31.5.4 Minimum Hardware Required
- •31.5.6 Result Interpretation
- •31.6.1 Anatomy
- •31.6.2 Pre-Procedure Instructions
- •31.6.3 Minimum Hardware Required
- •31.6.4 Procedure
- •31.6.5 Result Interpretation
- •31.7.1 Pre-Procedure Instructions
- •31.7.2 Minimum Hardware Required
- •31.7.3 Procedure
- •31.7.4 Result Interpretation
- •31.8 Conclusion
- •References
- •32.1 Introduction
- •32.2 Priapism
- •32.3 Erectile Dysfunction
- •32.3.2 Epidemiology
- •32.3.3 Aetiology
- •32.3.4 Pathophysiology
- •32.3.6 Imaging
- •32.3.7 Relevant Anatomy
- •32.3.7.2 Venous Anatomy
- •32.3.8 Penile Doppler
- •32.4.1 Indications
- •32.4.2 Contraindications
- •32.4.3 Equipment
- •32.4.4 Technical Aspects
- •32.4.5 Procedure Timing
- •32.4.6 Outcomes
- •32.4.7 Complications
- •32.4.8 Post-Procedural Care
- •32.5.1 Indications
- •32.5.2 Contraindications
- •32.5.3 Equipment
- •32.5.4 Technical Aspects
- •32.5.5 Outcomes
- •32.5.6 Complications
- •32.6.1 Indications
- •32.6.2 Contraindications
- •32.6.3 Equipment
- •32.6.4 Procedural Planning
- •32.6.5 Technical Aspects
- •32.6.6 Outcomes
- •32.6.7 Complications
- •32.7 Conclusion
- •References
- •33: Image-Guided Biopsy
- •33.1 Introduction
- •33.2 Biopsy Devices
- •33.3 Pre-Procedural Evaluation
- •33.4 Ultrasound-Guided Biopsy
- •33.5 CT-Guided Biopsy
- •33.6 MRI-Guided Biopsy
- •33.7.2 Breast
- •33.7.3 Lung
- •33.7.4 Mediastinum
- •33.7.5 Liver
- •33.7.6 Gallbladder
- •33.7.7 Spleen
- •33.7.8 Bowel
- •33.7.9 Retroperitoneum
- •33.7.11 Pelvis
- •33.7.12 Spine
- •33.7.13 Extremities
- •33.8 Conclusion
- •References
- •34: Image-Guided Drainage Procedures
- •34.1 Introduction
- •34.2 Etiology
- •34.4 Contraindications
- •34.5 Imaging Modalities
- •34.6 Pre-Procedure Evaluation
- •34.8 Post-Procedure Care
- •34.9 Complications
- •34.10.1 Postoperative Fluid Collection
- •34.10.2 Ascites
- •34.10.3 Liver Abscess
- •34.10.4 Peripancreatic Fluid Collection
- •34.10.5 Splenic Abscess
- •34.10.6 Appendicitis
- •34.10.8 Renal Abscess
- •34.10.9 Pelvic Abscess
- •34.10.10 Prostatic Abscess
- •34.11 Summary
- •References
- •35: Ablation Techniques
- •35.1 Introduction
- •35.2 Chemical Ablation
- •35.3 Thermal Ablation Techniques
- •35.3.1 Radiofrequency Ablation
- •35.3.2 Microwave Ablation
- •35.3.3 Cryoablation
- •35.3.4 High-Intensity Focused Ultrasound
- •35.3.5 Laser Ablation
- •35.4 Non-thermal Ablation Techniques
- •35.4.1 Irreversible Electroporation
- •35.6.1 Liver
- •35.6.2 Kidney
- •35.6.3 Lung
- •35.6.4 Breast
- •35.6.5 Thyroid
- •35.6.6 Musculoskeletal System
- •35.6.7 Nerve Ablation
- •35.7 Conclusion
- •References
- •36.1 Introduction
- •36.3 CT-Guided Biopsy
- •36.3.2 Complications
- •36.3.3 Technical Approaches
- •36.3.4.3 Paramaxillary Approach
- •36.3.4.4 Submastoid Approach
- •36.3.4.5 Transoral Approach
- •36.3.5.1 Anterolateral Approach
- •36.3.5.2 Posterolateral Approach
- •36.3.5.3 Posterior Approach
- •36.4 Ultrasound-Guided Biopsy/FNAC
- •36.4.2.5 Carotid Space
- •36.7 Conclusion
- •References
- •37: Nonvascular Thoracic Interventions
- •37.1 Introduction
- •37.2 Thoracic Drainage Procedures
- •37.2.1 Pre-Procedure Evaluation
- •37.2.2 Imaging
- •37.3 Thoracocentesis
- •37.3.1 Indications
- •37.3.2 Relative Contraindications
- •37.3.4 Technique
- •37.4.1 Indications
- •37.4.2 Contraindications
- •37.4.3 Drain Size
- •37.4.5 Post-Insertion Care
- •37.5 Intrapleural Fibrinolytic Therapy
- •37.5.1 Catheter Removal
- •37.6 Practice Points
- •37.7 Indwelling Pleural Catheter Insertion
- •37.7.1 Duration
- •37.8.1 Procedure
- •37.8.2 Trocar Drainage
- •37.8.3 Seldinger Technique
- •37.8.4 Post-Procedure Follow-Up
- •37.8.5 Removal
- •37.9 Complications
- •37.9.1 Thoracentesis Related
- •37.9.2 Drainage Chest Tube Related
- •37.9.3 IPC Related
- •37.11.1 Pre-Procedure Evaluation
- •37.11.3 Technique
- •37.11.4 Post-Procedure Care
- •37.11.5 Complications [11, 14, 15]
- •37.12.1 Indications [11, 19]
- •37.12.2 Contraindications [11, 19]
- •37.12.3 Technique
- •37.12.4 Post-Procedure Care
- •37.12.5 Complications
- •References
- •38.1 Introduction
- •38.2 Biliary Anatomy
- •38.3 Biliary Obstruction
- •38.4 Percutaneous Transhepatic Biliary Drainage
- •38.4.2 Indications
- •38.4.3 Contraindications
- •38.4.4 Technique
- •38.4.5 Post-Procedure Care
- •38.4.6 Complications
- •38.5 Biliary Stenting
- •38.5.1 Indications
- •38.5.2 Technique
- •38.7 Intraluminal Procedures Through Percutaneous Biliary Access
- •38.7.1 Endobiliary Biopsy
- •38.7.2 Intraluminal Brachytherapy
- •38.7.3 Gallstone Extraction
- •38.8 Percutaneous Cholecystostomy
- •38.8.1 Indications
- •38.8.2 Technique
- •References
- •39.1 Introduction
- •39.2 Percutaneous Gastrostomy
- •39.2.1 Indications
- •39.2.2 Contraindications
- •39.2.3 Pre-procedural Work-Up
- •39.2.4 Technique
- •39.2.6 Pull-Type PRG
- •39.3 Percutaneous Jejunostomy
- •39.3.1 Indications
- •39.3.2 Technique
- •39.4 Percutaneous Cecostomy
- •39.4.1 Indications
- •39.4.2 Technique
- •39.4.3 Post-procedure Care
- •39.5.1 Technique
- •39.6.1 Technique
- •39.6.3 Malignant Tracheoesophageal Fistula Stenting
- •39.6.5 Complications
- •References
- •40.1 Introduction
- •40.2 Percutaneous Nephrostomy (PCN)
- •40.2.5 Post-procedure Care
- •40.4.3 Ureteroarterial Fistula
- •References
- •41.1 Introduction
- •41.2 Fallopian Tube Recanalization (FTR)
- •41.2.1 Technique
- •41.2.2 Complications
- •41.2.3 Results
- •41.3 Amniocentesis
- •41.3.1 Indications
- •41.3.2 Contraindications [7]
- •41.3.4 Technique
- •41.3.5 Complications
- •41.4 Chorionic Villous Sampling (CVS)
- •41.4.1 Indications
- •41.4.2 Contraindications
- •41.4.4 Technique
- •41.4.5 Complications
- •41.5.1 Indications [15–19]
- •41.5.2 Contraindications [20–23]
- •41.5.3 Technique [15, 23]
- •41.5.4 Complications [15, 23, 24]
- •41.5.5 Outcome [23]
- •41.6.1 Technique
- •41.6.2 Complications
- •41.7.1 Contraindications
- •41.7.2 Technique
- •41.7.3 Complications
- •41.8.1 Technique
- •41.8.2 Complications
- •41.9.1 Technique
- •41.9.2 Complications [28, 44, 45]
- •References
- •42.1 Introduction
- •42.2 Breast Biopsy
- •42.2.2 USG-Guided Biopsy [1, 2]
- •42.2.3 MG-Guided Biopsy [3, 4]
- •42.2.4 MRI-Guided Biopsy [1, 11–13]
- •42.2.5 Vacuum-Assisted Biopsy [1, 4, 14, 15, 16]

34 Image-Guided Drainage Procedures
433
While large effusions can be tapped with the patient in a
supine position, mild effusions require the patient to be positioned in the sitting posture for aspiration of uid from the
posterior pleural recess. The uid can be sent for analysis of
uid protein and glucose, cell counts, gram stain, culture, and
GeneXpert depending on the clinical suspicion. Therapeutic
drainage may be needed if the effusion is large and is causing
respiratory distress to the patient. Simple effusions can be
drained by large volume thoracocentesis. A three-way connector is attached to the puncture needle, following which a
50 ml syringe and tubing leading to a collection bottle are
attached to either side of the three-way connector. Fluid is
aspirated using the syringe and discarded through the tubing.
More than 1.5L of uid should not be drained in the rst hour
to avoid re-expansion pulmonary edema.
Percutaneous catheter drainage is done for empyemas,
malignant effusions, hemothorax, and effusions associated
with acute pancreatitis. Empyemas are drained percutaneously if they are focal or uniloculated, and by surgical chest
tube placement if they are multiple, multiloculated, complex,
and extensive [8]. Catheters are inserted through the triangle
of safety that is bounded anteriorly by the posterior border of
the pectoralis major muscle, posteriorly by the latissimus
dorsi muscle, and inferiorly by the fth intercostal space.
Insertion at this site minimizes the risk of injury to major
blood vessels and nerves. Also, the needle and catheter
should be advanced along the superior border of the rib to
avoid injury to the neurovascular bundle that runs along its
inferior border. Pleural effusion drainage can be done under
USG guidance except in cases of hydropneumothorax, in
which air obscures the visualization on USG and CT becomes
necessary for guiding the procedure. Percutaneous catheters
within the pleural cavity should always be connected to a
drainage bag with an underwater seal to prevent the atmospheric air from being sucked into the pleural space.
Persistent, complex collections and organizing hemothorax
require the use of brinolytic agents. The commonly used
brinolytic agents include streptokinase 250,000IU daily for
7days, urokinase 100,000IU daily for 3days, and alteplase
10–25mg daily for 3days. The brinolytic agent is mixed in
100ml of normal saline and instilled into the septated effusion daily, following which the catheter is clamped for four
hours before drainage. Although the use of brinolytic can
improve the drainage of effusion, clinical improvement has
not been shown to be signicantly different from placebo in
randomized controlled trials [9]. Pneumothorax can be
drained percutaneously by inserting the catheter into the
anterior pleural recess under CT guidance.
Lung abscesses occur most commonly as a result of aspiration of oropharyngeal bacteria and occur usually in immunocompromised individuals. Majority of the lung abscesses
can be treated with the use of broad-spectrum antibiotics
alone. In case of abscesses that do not resolve with antibiotics, surgical or percutaneous drainage can be considered [8].
Chemical pleurodesis is indicated in recurrent malignant
pleural effusion, refractory symptomatic non-malignant pleural effusion, and recurrent spontaneous pneumothorax. The
various sclerosing agents used for pleurodesis are bleomycin
(60IU in 50ml normal saline), talc slurry, and doxycycline.
The effusion needs to be drained for the maximal sclerosant
effect to take place. The sclerosant is injected into the pleural
cavity and the drain is kept closed for three hours [10].
34.11 Summary
Percutaneous drainage of uid collections is a minimally
invasive technique that is commonly performed under image
guidance. It is associated with a reduced complication rate as
compared to surgical drainage. With the advent of advanced
imaging techniques, it has become the standard of care in the
management of uid collections in most cases.
References
1. Dariushnia SR, Mitchell JW, Chaudry G, Hogan MJ. Society of
Interventional Radiology quality improvement standards for imageguided percutaneous drainage and aspiration of abscesses and uid
collections. J Vasc Interv Radiol. 2020;31(4):662–666.e4.
2. Kumar RR, Kim JT, Haukoos JS, etal. Factors affecting the successful management of intra-abdominal abscesses with antibiotics and the need for percutaneous drainage. Dis Colon Rectum.
2006;49(2):183–9.
3. Patel IJ.Society of Interventional Radiology Consensus Guidelines
for the Periprocedural Management of Thrombotic and Bleeding
Risk in Patients Undergoing Percutaneous Image-Guided
Interventions-Part II: Recommendations. J Vasc Interv Radiol.
2019;30:18.
4. Chehab MA, Thakor AS, Tulin-Silver S, Connolly BL, Cahill AM,
Ward TJ, etal. Adult and Pediatric Antibiotic Prophylaxis during
Vascular and IR Procedures: A Society of Interventional Radiology
Practice Parameter Update Endorsed by the Cardiovascular and
Interventional Radiological Society of Europe and the Canadian
Association for Interventional Radiology. J Vasc Interv Radiol.
2018;29:1483–1501.e2.
5. Robert B, Yzet T, Regimbeau JM. Radiologic drainage of postoperative collections and abscesses. J Visc Surg. 2013;150(3,
Supplement):S11–8.
6. World Health Organization. PAIR: puncture, aspiration, injection,
re-aspiration. An option for the treatment of cystic echinococcosis.
2001. Accessed on June 30, 2022. Available from: http://whqlibdoc.
who.int/hq/2001/WHO_CDS_CSR_APH_2001.6.pdf.
7. Bharwani N, Patel S, Prabhudesai S, Fotheringham T, Power
N.Acute pancreatitis: the role of imaging in diagnosis and management. Clin Radiol. 2011 Feb;66(2):164–75.
8. Lorenz JM, Ray CE, Burke CT, Darcy MD, Fidelman N, Greene
FL, et al. American College of RadiologyACR Appropriateness
Criteria on radiologic management of infected uid collections.
American College of Radiology 2011. Accessed 30 June 2022.
9. Banka R, Terrington D, Mishra EK. Management of septated
malignant pleural effusions. Curr Pulmonol Rep. 2018;7(1):1–5.
10. Ali M, Surani S. Pleurodesis. In: StatPearls [Internet]. Treasure
Island (FL): StatPearls Publishing; 2022 [cited 2022 Jun30].
Available from: http://www.ncbi.nlm.nih.gov/books/NBK560685/.

Ablation Techniques
VishnuPrasadPulappadi andS.H.Chandrashekhara
35
Key Messages
1. Percutaneous ablation has become an effective treatment
option for malignancy as an alternative to surgical
resection.
2. It has a lower complication rate as compared to conventional surgery.
3. Thermal ablation techniques such as radiofrequency ablation, microwave ablation and cryoablation are the most
commonly used ones.
4. Ablation has been for the treatment of early-stage cancers
in the liver, kidney and lung, as well as for benign lesions
in the thyroid and breast.
5. Ablation is usually done under USG or CT guidance or a
combination of both.
35.1 Introduction
Image-guided ablation has evolved to become a common
therapeutic option for various tumours and other conditions.
It is considered an alternative to surgery, especially in earlystage cancers. Percutaneous ablation is minimally invasive
and has the advantage of shorter hospital stay and faster
recovery. The aim of this chapter is to discuss in detail the
various ablation techniques that are available and the common disease conditions for which they are performed.
Commonly used ablation techniques are summarised in
Fig.35.1 and are described in detail below. Techniques of
varicose vein ablation are discussed in detail separately in
the chapter on interventions in lower extremity veins.
V. P. Pulappadi (*)
Kovai Medical Center and Hospital, Coimbatore, India
S. H. Chandrashekhara
Department of Radiodiagnosis and Interventional Radiology,
IRCH, All India Institute of Medical Sciences, Delhi, India
© The Author(s), under exclusive license to Springer Nature Singapore Pte Ltd. 2024
S. H. Chandrashekhara (ed.), Textbook of Interventional Radiology, https://doi.org/10.1007/978-981-97-9601-4_35
435

436
V. P. Pulappadi and S. H. Chandrashekhara
Percutaneous Ablation
Chemical Ablation
Radiofrequency
Ablation
Fig. 35.1 Overview of percutaneous ablation techniques
Microwave
Ablation
Cryoablation Laser Ablation
Thermal Ablation Non-thermal Ablation
35.2 Chemical Ablation
Chemical ablation is less commonly used in clinical practice as compared to thermal ablation techniques. It has the
advantage of being less expensive as compared to thermal
ablation techniques. 95% ethanol and 50% acetic acid are
the agents used for chemical ablation. Once injected into the
centre of the tumour, they cause protein denaturation, cellular dehydration and ischaemia by small vessel thrombosis.
Tumours have more extracellular volume than normal liver,
facilitating easy diffusion of these chemical agents. The
advantage of chemical ablation over thermal ablation is its
cost- effectiveness and short procedure time. Ethanol tends
to diffuse into the tumour which is visualised as a hypoechoic
area on ultrasonography (USG). In the case of hepatocellular carcinoma (HCC), its spread is conned to the tumour by
the capsule and the surrounding cirrhotic liver parenchyma.
On the other hand, in metastatic lesions, ethanol diffuses out
into normal surrounding liver parenchyma, making it less
effective in these lesions. As in all ablation techniques, the
goal is to achieve ablation of 5–10mm margin of normal
tissue around the tumour. The total volume of ethanol to be
injected is calculated by the formula 4/3 π (r+0.5)3, where
r is the radius of the tumour. Multiple sessions may be
required for larger lesions, and a maximum of 10–20ml is
injected in one session. For acetic acid injection, a volume
equal to three times the diameter of the lesion is used and
1–2ml is injected in one session. Acetic acid has the ability
to diffuse across the septa within the tumour and is therefore
associated with a lower tumour recurrence rate than alcohol.
Complications include pain, infection, haemoglobinuria and
transient renal failure.
High Intensity
Focussed
Ultrasound
Irreversible
Electroporation
35.3 Thermal Ablation Techniques
Thermal ablation involves tissue heating or rapid cooling to
induce cell death. Raising the tissue temperature to more than
60°C results in coagulation necrosis. Commonly used thermal
ablation techniques include radiofrequency ablation (RFA),
microwave ablation (MWA) and cryoablation (Fig.35.2).
35.3.1 Radiofrequency Ablation
High-frequency radiofrequency energy is passed through the
electrode to cause rapid oscillation of tissue ions that generate frictional heat. Generators with capacities of 60–250W
are used in common practice. Heat transfer occurs through
conduction, a relatively slow process that depends upon the
tissue conductivity. Probes used can be either unipolar, which
requires a grounding pad, or bipolar, in which the ablation
zone is created between two electrodes. Temperature within
the tissue rises to 60–100 °C resulting in necrosis.
Temperature above 100°C is not desired due to tissue boiling and charring. The ablation zone has to include 5–10 mm
of normal tissue around the tumor to reduce the risk of recurrence. Charring of tissue around the probe is a major drawback of RFA as it dampens the heat transmission and reduces
the size of the ablation zone. Multiple modications have
been made to the electrodes to increase the size of the ablation zone [1]. They include:
• Internally cooled tip electrode to reduce charring around
the tip.
• Clustered or multi-tined expandable electrodes.

bc
35 Ablation Techniques
437
a
Fig. 35.2 Various ablation systems. (a) Radiofrequency ablation system (Celon Power, Olympus). (b) Microwave ablation system (Saberwave,
Eco). (c) Cryoablation system (Prosense, Icecure)
• Use of rapidly switching multiple electrodes.
• Instillation of interstitial saline from the tip of the electrode to increase the spread of thermal energy and increase
the ionicity of the tissue.
Energy pulsing is another method for increasing the abla-
tion area, where rapidly alternating high and low energy
deposition is performed, facilitating cooling of tissue adjacent to the probe. Another drawback of RFA is the heat sink
effect, in which the generated heat is carried away from the
tumour by blood owing through a large blood vessel in its
vicinity. This effect can be reduced by balloon occlusion of
the hepatic artery branch during the ablation.
35.3.2 Microwave Ablation
In MWA, a rapidly oscillating electromagnetic eld is generated around the probe, which results in the oscillation of polar
water molecules due to their tendency to align along the magnetic eld. The resultant increase in the kinetic energy causes
the local tissue temperature to rise. The frequency range commonly used for ablation is 915–2450MHz [2]. While RFA
depends mainly on tissue conductivity for achieving the ablation, MWA acts by direct heat energy deposition onto the tissue up to 2cm around the antenna. The spread of microwaves
in tissues depends upon the permittivity, i.e., the ability of the
tissue to store energy. Tumours have higher permittivity than
normal tissues, and a higher difference in permittivity between
the tumour and the surrounding tissue, such as in lung and
breast tumours, results in better energy deposition [2]. As
microwaves tend to heat up the shaft of the probe, the maximum power that can be set is 60W, in order to prevent thermal injury along the puncture tract [2]. However, the newer
generation MWA systems have antenna cooling systems with
high-power generators [1]. This facilitates longer ablation
times and spherical zone of ablation as compared to the older
systems [2]. Similar to the other thermal ablation techniques,
the zone of ablation can be increased by the simultaneous use
of multiple electrodes.
MWA has various advantages over RFA:
• As the passage of microwaves doesn’t depend upon tissue
impedance, MWA results in a large zone of ablation in a
short period of time as compared to RFA.
• Greater heating is attained with microwaves as compared
to RFA, as the maximum temperature attainable in RFA is
limited by the boiling temperature of the soft tissue
(around 100°C), beyond which tissue charring starts.
• As higher frequencies are used, high-energy microwaves
can be generated without the need for grounding pads.
• Heat sink effect is less due to lower dependence on distribution of heat by conduction.
35.3.3 Cryoablation
Cryoablation involves cooling down the tissue, resulting in
intra- and extracellular ice formation. Rapid cooling causes
intracellular ice formation and direct damage to cell organelles, while slow cooling promotes extracellular ice formation and cell dehydration [1]. The rapid cooling is brought
about by making use of the Joule Thomson effect, wherein
rapid expansion of gases causes rapid drop in temperature to
−20 to –40°C.Argon and liquid nitrogen are the most com-
monly used cryogens. Helium is often used for an active
thaw cycle, as rapid expansion of Helium raises the tissue
temperature. Two freeze-thaw cycles, each consisting of
10–15minutes of freezing and 8–10minutes of thawing are
performed in most of the solid tumours. In lung tumours,
however, three cycles are performed, wherein the rst cycle
enables haemorrhage within the tumour for better conduction. The blood ow is restored during thawing, resulting in
a washout of cellular debris into the systemic circulation.

438
V. P. Pulappadi and S. H. Chandrashekhara
This may result in ‘cryoshock’, which is similar to disseminated intravascular coagulation, leading to an increased risk
of bleeding [1].
The advantages of cryoablation over the other thermal
ablation methods are:
• Real-time visualisation of ice ball formation within the
tumour on USG, CT or MRI during the ablation.
• Reduced peri-procedural pain due to hypothermiainduced nerve block.
Ice ball formation is seen on USG as a hyperechoic area
with posterior acoustic shadowing, on CT as an area of low
attenuation and on MRI as signal void. However, the area of
necrosis tends to be around 5mm less than the margin of the
ice ball [3]. The area of ablation depends on direct diffusion
of thermal energy unlike RFA and MWA, and in turn depends
upon the surface area of the probe. Therefore, cryoablation
often requires the placement of multiple probes and longer
ablation times as compared to other thermal ablation techniques [1]. Cryoablation is preferred over other thermal ablation techniques in tumours that are close to vital organs due
to precise visualization of ice ball formation.
35.3.4 High-Intensity Focused Ultrasound
High-intensity focussed ultrasound (HIFU) is a completely
non-invasive technique of ablation in which high-energy
ultrasound waves with a frequency range of 1–5MHz are
generated by a piezoelectric transducer. The ultrasound
waves are then focussed onto a small area within the tumour
using an acoustic lens or paraboloid reector, thereby
increasing the temperature to 50–100°C.Degassed water is
used to facilitate the transmission of ultrasound waves from
the transducer to the body. It has an acoustic impedance similar to soft tissue, thereby reducing sound absorption and
reection. HIFU can be performed under USG or MRI guidance. While the non-invasive nature of HIFU is advantageous, long procedure time is a major drawback.
35.3.5 Laser Ablation
Laser photocoagulation involves the use of light pulses to
generate heat. It involves placement of multiple needles in an
array within the tumour followed by the passage of laser
pulses through optical bres into the needles. Nd:Yag laser,
with a wavelength of 1064 nm, is most commonly used.
Although widely used for ablation of varicose veins, laser is
not commonly used for ablation of solid tumours.
35.4 Non-thermal Ablation Techniques
35.4.1 Irreversible Electroporation
Irreversible electroporation (IRE) is a non-thermal ablation technique. It involves creation of pores on the cell
membrane using electric current. Use of electric pulses
above a threshold duration and number results in irreversible damage to cell membrane and cell death. IRE has various advantages over thermal ablation techniques. As it
involves administration of electric pulses for a duration of
only a few milliseconds and doesn’t require the tissue temperature to change, the time of ablation is considerably
less compared to thermal ablation techniques. As opposed
to thermal ablation that causes cell death by necrosis, IRE
results in apoptosis, which facilitates faster regeneration of
normal cells in the involved organs. Also, adjoining blood
vessels and bile ducts are not damaged as IRE doesn’t
affect the protein scaffolding of these structures [4]. Due
to the muscle excitation produced by the electric current,
administration of general anaesthesia with muscle relaxant
is essential for performing this procedure. The electric current can also excite the myocardium and produce arrhythmias. Hence ECG synchronisation is necessary to ensure
that the current is delivered during the refractory phase of
the cardiac cycle, i.e., immediately following the initiation
of QRS complex [5].
35.5 Choice ofImaging Modality
forGuidance
The various imaging modalities available for guiding ablation are USG, CT, MRI and uoroscopy.
USG is the most commonly used modality for ablation of
liver and renal tumours. It has the advantage of low cost,
easy availability and real-time visualisation of the needle
during the procedure.
CT is used for guidance for ablation of lesions that cannot
be visualised on USG, especially lung tumours and osteoid
osteoma. It is also useful in delineating the relationship of
the tumour with the surrounding structures when pneumodissection or hydrodissection is utilised.
Very commonly, a combination of these modalities is
used, wherein USG is used to guide probe placement
into the tumour in real time and CT is used to confirm
the position of the probe within the centre of the tumour
and to check for post-procedure complications, such as
haemorrhage.
MRI is used in certain situations where the lesion is not
visualised on USG or CT, such as breast or prostate lesions.

35 Ablation Techniques
439
35.6 Specic Organ Considerations
35.6.1 Liver
Percutaneous ablation is one of the standard curative treatment options in hepatocellular carcinoma. In addition to
HCC, ablation is used for the treatment of metastasis from
colorectal carcinoma and neuroendocrine tumours as well as
for benign lesions including giant haemangiomas and hepatic
adenomas. Randomised controlled trials have shown that
ablation has similar recurrence-free survival rates and overall
survival rates as compared to surgical resection in HCCs
≤3cm in diameter, with lower procedure-related complications [6, 7]. According to the Barcelona Clinic Liver Cancer
stating system, ablation is performed in very early and early
stage HCCs (Fig.35.3) [8]. In patients who are otherwise
eligible for transplant, ablation can be used as a bridge therapy when there is a long waiting period for the transplant [9].
Tumours that are 3–5cm in diameter benet from a combination of ablation and trans-arterial chemoembolisation
(TACE) [10]. They can be performed in the same sitting or
two weeks apart. Ablation can be performed in patients with
colorectal metastasis who are not candidates for surgery, provided that the lesions are up to ve in number, with each of
them being ≤3cm in size. Solitary intrahepatic cholangiocarcinoma ≤3cm in size can also be treated with ablation
[11].
The absolute contraindications for percutaneous ablation
include uncorrectable coagulopathy, intravascular extension,
tumours located <10mm from the right or left hepatic duct,
intrahepatic biliary radical dilation and exophytic tumour,
where direct puncture of the tumour can result in tumour
seeding into the peritoneal cavity. Relative contraindications
include extrahepatic metastasis, ascites and tumours close to
stomach, colon or gall bladder [11].
RFA and MWA have lower risk of bleeding complications
compared to cryoablation in cirrhotic livers [1] (Figs.35.4,
35.5, and 35.6). Cryoablation can be used in tumours located
close to central bile ducts as it causes less damage to the
ducts as compared to RFA or MWA.RFA is associated with
a greater heat sink effect than MWA, but it can be reduced by
balloon ination within the adjoining large vessel to arrest
Very early stage (0)
• Single lesion ≤2 cm
• Preserved liver function
• PS 0
Potential candidate
for liver transplant
No
Ye s
Normal High
Ablation Resection
Single
nodule
Portal pressure,
bilirubin
Early stage (A)
• <3 nodules, each < 3 cm
• Preserved liver function
• PS 0
Multiple
nodules
Contraindications
to transplant
Present
Ablation Tr ansplant
Absent
Hepatocellular carcinoma
Intermediate stage (B)
• Multinodular
• Preserved liver function
• PS 0
Fulfilling extended
liver transplant
criteria
Successful
downstaging
Treatment
failed or not
feasible
Well-defined
nodules, preserved
portal flow, selective
access possible
Transar terial
chemoemboization
Transar terial
chemoemboization/
radioembolization
Advanced stage (C) Te rminal stage (D)
• Portal vein invasion/ extrahepatic
spread
• Preserved liver function.
• PS 1-2
Diffuse/
Infiltrative/
extensive bilobar
involvement
Systemic treatment
Atezolizumab-Bevacizumab/
Durvalumab-Tremelimumab,
Sorafenib, Lenvatinib
Treatment failed or
not feasible
• Any tumour burden
• End-stage liver function
• PS 3-4
Best supportive
care
Treatment failed or
not feasible
Fig. 35.3 Barcelona Clinic Liver Cancer staging system. ECOG-PS Eastern Cooperative Oncology Group-performance status

440
V. P. Pulappadi and S. H. Chandrashekhara
abc
Fig. 35.4 Ultrasound-guided RFA of solitary metastasis using umbrella-shaped RF probe. (a) Ultrasound showing solitary lesion in the right lobe
of the liver. (b) and (c) RFA ablation was done for the same using ultrasound guidance
there is no conduction of electric current involved. Carbon
dioxide is preferred over room air due to lower risk of air
embolism [11]. During ablation of peribiliary lesions, uid
instillation through nasobiliary or percutaneous transhepatic
biliary access would be helpful in reducing the risk of injury
to the biliary tree. Once the ablation is complete, tract ablation is performed to prevent seeding of tumour cells. into the
peritoneal cavity.
Post-ablation syndrome is common after ablation and is
characterised by low-grade fever, malaise and vomiting.
Other complications include haemorrhage, infection, haemothorax, pneumothorax and bowel perforation.
Fig. 35.5 Schematic diagram of RF ablation of peripheral liver lesion.
Hydrodissection is done to avoid injury to diaphragm
the blood ow. Routine antibiotic prophylaxis is recommended— 1g cefazolin administered intravenously one hour
prior to the procedure. In patients with sphincter of Oddi
dysfunction and biliary obstruction who are at high risk of
infection due to bacterial colonisation in the biliary tract,
1.5g ampicillin-sulbactam is recommended [12]. Ablation
of tumours poses a challenge when they are in close proximity to the adjoining organs such as the stomach or colon. In
such cases, hydrodissection using 5% dextrose or normal
saline or pneumodissection using carbon dioxide is used to
separate the tumour from the adjacent organs. During RFA,
5% dextrose is used instead of normal saline as the latter
conducts electric current (Fig.35.5). During MWA and cryoablation, normal saline can be used for hydrodissection as
35.6.2 Kidney
Percutaneous ablation is one of the treatment options for
early renal cell carcinoma (RCC). Surgical resection has
been the standard of care for RCCs. However, RFA, MWA
and cryoablation are now in common use for the treatment of
RCCs. It can be done under USG or CT guidance. Multiphasic
contrast-enhanced CT or MRI is performed to ascertain the
size, location and enhancement characteristics of the tumour.
Percutaneous biopsy is necessary prior to the ablation to conrm the histological nature of the mass. The American Joint
Committee on Cancer (AJCC) TNM staging system is used
for staging of renal cell carcinomas, and ablation is indicated
in stage I RCCs [13, 14]. It includes tumours that are ≤7cm
in greatest dimension and limited to the kidney without any
nodal involvement or distant metastasis. Complete ablation
is achieved in tumours that are <3cm in maximum dimension, while in larger tumours, complete necrosis may not be
achieved [14]. The other treatment options available for
stage I RCC are partial nephrectomy and active surveillance.
Ablation has the advantage over surgery of preserving the
normal renal parenchyma and therefore the renal function.
Ablation is therefore preferred over partial nephrectomy in

35 Ablation Techniques
441
Fig. 35.6 Microwave
ablation of the solitary liver
metastasis under CT
guidance. Ultrasound (a)
image showing heteroechoic
liver lesion. The lesion was
ablated using MWA (b and c).
Post-ablation CT (d) shows
complete ablation of the
lesion with air pockets within.
Note is made of minimal
perihepatic uid collection
following the procedure
ab
cd
patients with single functioning kidney, impaired renal function, multifocal tumour or multiple comorbidities with high
risk for complications during surgery and in those patients
who refuse to undergo surgery. The contraindications for
ablation include uncorrectable coagulopathy and extensive
spinal deformity that precludes percutaneous needle placement [14].
Pre-procedure antibiotics are not routinely recommended.
However, patients with diabetes mellitus, ileal conduit or
ureteric stent in place are at high risk of infection, and it is
recommended to administer 1g ceftriaxone intravenously in
these patients one hour prior to the procedure [12]. In case of
tumours that are in close proximity to the adjacent organs,
hydrodissection or pneumodissection can be performed similar to liver tumour ablation to reduce the risk of injury to
these organs. Pyeloperfusion is used to reduce thermal injury
to the pelvicalyceal system during ablation of centrally
located tumours. It can be performed in an antegrade manner
through percutaneous nephrostomy or retrograde manner
through a ureteric stent. Adjunctive transarterial embolisation can increase the efcacy of ablation by promoting
tumour necrosis [14].
Most common complication is haemorrhage, which is usually self-limiting, but rarely requires blood transfusion and transarterial embolisation. Other complications include ureteric
injury, bowel perforation, infection and pneumothorax [14].
35.6.3 Lung
Ablation can be offered for inoperable non-small cell lung
carcinomas (NSCLC) and lung metastases from distant primary malignancies. Although surgery is the best treatment
for stage I NSCLC, many patients have poor pulmonary
reserve and are not candidates for surgery. Stereotactic radiotherapy and RFA are feasible alternatives in such patients.
Ablation is indicated in tumours <2cm in size (stage T1a and
T1b). Similarly, solitary lung metastasis from a distant primary malignancy can be treated by ablation if surgery is not
feasible. Ablation can be performed in lung metastasis from
colorectal carcinoma for up to three lesions, provided that
each lesion is ≤2cm in size. Ablation may also be performed
in cases of metastasis from HCC, RCC, melanoma and sarcoma, although limited evidence is available regarding its
role in comparison to the standard treatment options [15].
RFA is associated with the disadvantage of poor conductivity
of electric current through the lung parenchyma due to the
presence of air within it. Due to lower risk of thermal injury
and reduced incidence of pain, cryoablation is useful in
lesions close to the mediastinum or the chest wall. In lesions
that recur after radiation therapy, ablation can have a large
zone of necrosis but with high risk of complications [1].
Ablation of bilateral lung nodules can be done, but not in the
same sitting, to avoid bilateral pneumothorax [16].

442
V. P. Pulappadi and S. H. Chandrashekhara
Positron emission tomography (PET) CT needs to be
done prior to the procedure to rule out lymph node involvement and distant metastasis. The histopathological nature of
the nodule needs to be conrmed prior to ablation by percutaneous or endobronchial sampling in case of primary lung
lesions. Biopsy is not required in cases of lung metastases
where the nature of the primary malignancy is known.
Needle path is planned through normal lung parenchyma of
>2cm thickness to reduce the risk of thermal injury to chest
wall and to reduce the risk of air leak when the tumour
shrinks during the ablation. As opposed to other organs, tract
ablation is avoided in lungs to reduce the risk of pneumothorax [1]. Articial pneumothorax is used while ablating subpleural lesions to avoid injury to the parietal pleura or
mediastinal structures. Complete ablation is seen on postprocedure CT as ground glass opacity with 1cm of circumferential margin around the tumour [15].
Contraindications include tumours located <1 cm from
the hilum, large vessel, main bronchus, trachea or oesophagus, uncorrectable coagulopathy and severe lung disease.
Ablation is not recommended in small cell lung carcinoma as
it usually presents in the advanced stages [15]. Complications
include pain, pleural effusion, pneumothorax, pulmonary
haemorrhage, abscess and air embolism. A chest radiograph
is recommended 4hours after the procedure to exclude pneumothorax [15].
35.6.4 Breast
Ablation has become one of the treatment options for benign
broadenoma of the breast. Ablation is indicated for biopsyproven broadenomas that are less than 4cm in diameter
[17]. While cryoablation is the most commonly used technique, RFA, MWA and HIFU are also used for benign and
malignant lesions of the breast. General anaesthesia is often
required during the ablation of breast lesions due to associated pain.
Ablation has also emerged as a treatment option for early
breast cancer. It can be done in breast carcinomas that are
<2cm in size, located >1cm from the skin and lack carcinoma in situ component. Although the treatment success rate
ranges from 73 to 100%, ablation is often followed by surgical resection [18, 19]. While USG is most commonly used to
guide needle placement, contrast-enhanced MRI is the preferred imaging modality for treatment planning and for
assessment of treatment response. Skin necrosis is a potential complication that can occur when the lesion is close to
the skin, but it can be prevented by the placement of saline
bags over the skin or by hydrodissection.
35.6.5 Thyroid
Percutaneous ablation is indicated as an alternative to surgery in large benign thyroid nodules that cause pressure
symptoms or cosmetic concerns. It is indicated in TI-RADS
2 benign nodules and is usually done in nodules >3cm in
size. In nodules with suspicious features (TI-RADS 3 and 4),
ne needle aspiration cytology should be performed to conrm the diagnosis prior to ablation. Serum calcitonin levels
may be done to rule out medullary carcinoma as it may not
show high-risk features on USG. Ablation is avoided in
TI-RADS 5 lesions that have high-risk features [20].
Although the role of ablation is not well established in thyroid malignancy, it can be performed for low-risk papillary
carcinomas that are <2 cm in size [21]. Thyroid function
should be assessed prior to ablation. In patients with hoarseness of voice, laryngoscopy is advised to assess the vocal
cord function.
RFA and laser ablation are the recommended rst-line
ablation techniques, followed by MWA.Aspiration followed
by ethanol ablation is the preferred ablation technique for
simple cysts. Although ablation is not recommended as a
rst-line treatment option for autonomously functioning thyroid nodules due to low rates of restoration of normal thyroid
function, it can be used to reduce the size of large nodules in
conjunction with radioactive iodine and also for small nodules (<10ml) with incomplete suppression of normal thyroid
tissue [20]. The procedure can be done under local anaesthesia and conscious sedation.
Common complications include pain and hematoma.
Vocal cord palsy can occur due injury to recurrent laryngeal
nerve during ablation of nodules located in the paratracheal
region. Hydrodissection is helpful to avoid injury to vital
structures located <5mm from the lesion. Nodule rupture
with uid collection around the thyroid gland may rarely
occur [20].
35.6.6 Musculoskeletal System
Ablation has been widely used for the treatment of osteoid
osteoma (Fig.35.7). It is a benign lesion that tends to occur
in young adults and presents with pain that typically increases
at night and gets relieved with non-steroidal antiinammatory drugs (NSAIDs). Ablation is offered for
patients who have persistent pain that is not relieved with
NSAIDs. RFA is the preferred modality for ablation and it is
performed under CT guidance. It has a success rate of up to
100% with a recurrence rate of 5% [22]. General or spinal
anaesthesia is usually required due to the pain associated

35 Ablation Techniques
Figs. 35.7 CT-guided RFA
ablation of osteoid osteoma.
(a) CT image shows osteoid
osteoma in left upper femur.
(b) It was ablated using RFA
under CT guidance
443
ab
with the procedure. Bone biopsy needle is used to obtain
access into the lesion. Kirschner wire or bone drill may also
be used for obtaining access. RFA probe is then advanced
into the lesion and ablation is done till 0.6kJ energy is deposited into the lesion.
Percutaneous ablation is a treatment option for painful
bone metastasis. Although radiotherapy is the rst-line treatment for metastasis, its delayed onset of treatment effect
makes ablation a feasible alternative for lesions that are
accessible by the percutaneous route. Cryoablation is the
preferred ablation technique because of its rapid pain relief
[1].
35.6.7 Nerve Ablation
Various ablation techniques have also been used for the control of neuropathic pain. Pulsed RFA is one of the treatment
options for neuromodulation, wherein the energy is deposited in pulses, allowing cooling of the tissue between the
pulses. It provides pain relief by inhibiting synaptic transmission while at the same time avoiding permanent tissue
damage [23].
Neurolysis involves causing permanent damage to the
nerves using thermal ablation techniques such as RFA or
cryoablation, or chemical ablation with alcohol or phenol.
Ninety-ve percent alcohol mixed with bupivacaine and
iodinated contrast agent in the ratio of 6:3:1 is commonly
used [23]. During thermal ablation, the probe is kept as
parallel to the axis of the nerve as possible to maximise
the length of ablation. Neurolysis is commonly performed
for celiac plexus block, trigeminal neuralgia, piriformis
syndrome, pudendal neuralgia and facet joint syndrome
[23].
35.7 Conclusion
Percutaneous ablation has emerged as a minimally invasive
alternative to surgical resection in a variety of disease conditions. It is a safe and easily performable procedure with low
complication rates. Newer advances in ablation techniques
continue to broaden the spectrum of indications for percutaneous ablation.
References
1. Hinshaw JL, Lubner MG, Ziemlewicz TJ, Lee FT, Brace
CL.Percutaneous tumor ablation tools: microwave, radiofrequency,
or cryoablation—what should you use and why? Radiographics.
2014;34(5):1344–62.
2. de Baere T, Deschamps F.New tumor ablation techniques for cancer treatment (microwave, electroporation). Diagn Interv Imaging.
2014;95(7–8):677–82.
3. Littrup PJ, Jallad B, Vorugu V, Littrup G, Currier B, George
M, et al. Lethal isotherms of cryoablation in a phantom study:
effects of heat load, probe size and number. J Vasc Interv Radiol.
2009;20(10):1343–51.
4. Lee EW, Thai S, Kee ST. Irreversible electroporation: a novel
image-guided cancer therapy. Gut Liver. 2010;4(Suppl.1):S99.
5. O’Neill CH, Martin RCG. Cardiac synchronization and
arrhythmia during irreversible electroporation. J Surg Oncol.
2020;122(3):407–11.
6. Takayama T, Hasegawa K, Izumi N, Kudo M, Shimada M,
Yamanaka N, et al. Surgery versus radiofrequency ablation for
small hepatocellular carcinoma: a randomized controlled trial
(SURF trial). Liver Cancer. 2021;11(3):209–18.
7. Xia Y, Li J, Liu G, Wang K, Qian G, Lu Z, etal. Long-term effects
of repeat hepatectomy vs percutaneous radiofrequency ablation
among patients with recurrent hepatocellular carcinoma. JAMA
Oncol. 2020;6(2):255–63.
8. Reig M, Forner A, Rimola J, Ferrer-Fàbrega J, Burrel M,
Garcia-Criado Á, et al. BCLC strategy for prognosis prediction and treatment recommendation: the 2022 update. J Hepatol.
2022;76(3):681–93.
Соседние файлы в папке Библиотека им академика М.И. Перельмана
